Implanted defibrillators in young hypertrophic cardiomyopathy patients: A multicenter study

Pediatric Cardiology

Volumn 34, Issue 7, 2013, Pages 1620-1627

  Kamp, Anna N ^a   Von Bergen, Nicholas H ^b   Henrikson, Charles A ^c,d   Makhoul, Majd ^e   Saarel, Elizabeth V ^f   Lapage, Martin J ^g   Russell, Mark W ^g   Strieper, Margaret ^e   Yu, Sunkyung ^g   Dick, Macdonald ^g   Day, Sharlene M ^g,h   Bradley, David J ^g  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA CHILDREN S HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h Cardiovascular Center   (United States)

Author keywords

Hypertrophic cardiomyopathy; Implantable cardioverter defibrillator; Pediatric; Young adult

Indexed keywords

ADOLESCENT; AGE; ARTICLE; CARDIOVASCULAR MORTALITY; DEVICE INFECTION; FEMALE; FOLLOW UP; GENERATOR; HEART ARRHYTHMIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; PRIMARY PREVENTION; RETROSPECTIVE STUDY; RISK REDUCTION; SECONDARY PREVENTION; SUDDEN CARDIAC DEATH;

CARDIOMYOPATHY, HYPERTROPHIC; CHILD; CHILD, PRESCHOOL; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84885387979     PISSN: 01720643     EISSN: 14321971     Source Type: Journal    
DOI: 10.1007/s00246-013-0676-6     Document Type: Article

References (28)

1. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS (2008) Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 51:1369-1374
2. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225-237
3. Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L (2003) Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. PACE 26:1887-1896
4. Berul CI, Van Hare GF, Kertesz NJ, Dubin AM, Cecchin F, Collins KK, Cannon BC, Alexander ME, Triedman JK, Walsh EP, Friedman RA (2008) Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol 51:1685-1691
5. Blom NA (2008) Implantable cardioverter-defibrillators in children. PACE 31(Suppl 1):S32-S34
6. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, Jacobs AK, Smith SC Jr, Anderson JL, Albert NM, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Krumholz HM, Kushner FG, Ohman EM, Page RL, Stevenson WG, Tarkington LG (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 142:e153-e203
7. Goldenberg I, Gillespie J, Moss AJ, Hall WJ, Klein H, McNitt S, Brown MW, Cygankiewicz I, Zareba W (2010) Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 122:1265-1271
8. Lawrence D, Von Bergen N, Law IH, Bradley DJ, Dick M II, Frias PA, Streiper MJ, Fischbach PS (2009) Inappropriate ICD discharges in single-chamber versus dual-chamber devices in the pediatric and young adult population. J Cardiovasc Electrophysiol 20:287-290
9. Leonardi S, Raineri C, De Ferrari GM, Ghio S, Scelsi L, Pasotti M, Tagliani M, Valentini A, Dore R, Raisaro A, Arbustini E (2009) Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. Eur Heart J 30:2003-2010
10. Liang K, Zeger S (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13-22
11. Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA (2009) Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart 95:709-714
12. Marian AJ (2010) Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest 40:360-369
13. Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287:1308-1320
14. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH III, Spirito P, Ten Cate FJ, Wigle ED (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687-1713
15. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA III, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P (2007) Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298:405-412
16. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ (2003) Nonsustained ventricular tachycardia in hypertrophic cardiomyopathy. J Am Coll Cardiol 42:873-879
17. Nannenberg EA, Michels M, Christiaans I, Majoor-Krakauer D, Hoedemaekers YM, van Tintelen JP, Lombardi MP, Ten Cate FJ, Schinkel AF, Tijssen JG, van Langen IM, Wilde AA, Sijbrands EJ (2011) Mortality risk of untreated Myosin-binding protein C-related hypertrophic cardiomyopathy: insight into the natural history. J Am Coll Cardiol 58:2406-2414
18. O'Mahony C, Lambiase PD, Quarta G, Cardona M, Calcagnino M, Tsovolas K, Al-Shaikh S, Rahman SM, Arnous S, Jones S, McKenna W, Elliott P (2012) The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart 98:116-125
19. Pablo Kaski J, Tome Esteban MT, Lowe M, Sporton S, Rees P, Deanfield JE, McKenna WJ, Elliott PM (2007) Outcomes after implantable cardioverter- defibrillator treatment in children with hypertrophic cardiomyopathy. Heart 93:372-374
20. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ (1997) Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 96:2987-2991
21. Silka MJ, Kron J, Dunnigan A, Dick M II (1993) Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The pediatric electrophysiology society. Circulation 87:800-807
22. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ (2000) Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342:1778-1785
23. Spirito P, Autore C, Rapezzi C, Bernabo P, Badagliacca R, Maron MS, Bongioanni S, Coccolo F, Estes NA, Barilla CS, Biagini E, Quarta G, Conte MR, Bruzzi P, Maron BJ (2009) Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 119:1703-1710
24. Suk T, Edwards C, Hart H, Christiansen JP (2008) Myocardial scar detected by contrast-enhanced cardiac magnetic resonance imaging is associated with ventricular tachycardia in hypertrophic cardiomyopathy patients. Heart Lung Circ 17:370-374
25. Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterlinski M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczynska-Mazuruk R, Ruzyllo W, Szwed H (2010) Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol 21:883-889
26. Von Bergen NH, Atkins DL, Dick M II, Bradley DJ, Etheridge SP, Saarel EV, Fischbach PS, Balaji S, Sreeram N, Evans WN, Law IH (2011) Multicenter study of the effectiveness of implantable cardioverter defibrillators in children and young adults with heart disease. Pediatr Cardiol 32:399-405
27. Walsh EP (2008) Practical aspects of implantable defibrillator therapy in patients with congenital heart disease. PACE 31(Suppl 1):S38-S40
28. Wordsworth S, Leal J, Blair E, Legood R, Thomson K, Seller A, Taylor J, Watkins H (2010) DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J 31:926-935